Home Anti-β2-Glycoprotein I ELISA: Methodology, Determination of Cut-off Values in 434 Healthy Caucasians and Evaluation of Monoclonal Antibodies as Possible International Standards
Article
Licensed
Unlicensed Requires Authentication

Anti-β2-Glycoprotein I ELISA: Methodology, Determination of Cut-off Values in 434 Healthy Caucasians and Evaluation of Monoclonal Antibodies as Possible International Standards

  • Šaa čučnik , Aleš Ambrožič , Borut Božič , Milan Skitek and Tanja Kveder
Published/Copyright: June 1, 2005
Become an author with De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 38 Issue 8

Abstract

Antibodies against β2-glycoprotein I are among the most commonly detected subset of antiphospholipid antibodies. The inter-laboratory comparability of results is hardly possible due to methodological differences, lack of international standards and different cut-off values. We evaluated an ELISA for the detection of anti-β2-glycoprotein I using the analytical goals based on biological variations for similar analytes (immunoglobulins). By our ELISA we fulfilled the optimal (IgA, IgM) or minimal (IgG) analytical goals in longterm imprecision. The determination of cut-off values was based on the frequency distribution of results obtained on 434 healthy Caucasians. To aim at a better inter-laboratory comparability we tested two monoclonal antibodies as possible calibrators: HCAL (IgG) and EY2C9 (IgM). Binding properties determined by dilutional curves showed great similarities with polyclonal sera, used as in-house standards. Cut-off values were expressed by concentrations of IgG and IgM monoclonal antibodies (4.5 and 25.3 μg/l). Our study shows the possibility for a successful application of analytical goals based on biological variation even when data for a particular analyte are not available. The expression of cut-off values, obtained on a large scale Caucasian population, by the concentration of IgG and IgM monoclonal antibodies could make possible a more reliable inter-laboratory comparison of data.

:
Published Online: 2005-06-01
Published in Print: 2000-08-21

Copyright © 2000 by Walter de Gruyter GmbH & Co. KG

Articles in the same Issue

  1. Changes of the Coagulation and Fibrinolysis System in Malignancy: Their possible Impact on Future Diagnostic and Therapeutic Procedures
  2. Laboratory Support of the Clinical Nutrition Service
  3. A new Method for Fast Haptoglobin Phenotyping and Hemoglobin Binding Capacity Calculation Based on Capillary Zone Electrophoresis
  4. Apolipoprotein E Polymorphism and Serum Concentration in Alzheimer's Disease in Nine European Centres: the ApoEurope Study
  5. Association of the Apolipoprotein B Gene Polymorphisms with Cholesterol Levels and Response to Fluvastatin in Brazilian Individuals with High Risk for Coronary Heart Disease
  6. Antioxidant Status, Erythrocyte Membrane Lipid Peroxidation and Osmotic Fragility in Malignant Lymphoma Patients
  7. Determination of H+/K+-ATPase Activity in Human Gastric Biopsy Specimens
  8. European Cerebrospinal Fluid Consensus Group a TeamRoom (Lotus Notes)-Based Communication Network
  9. Automated Enzymatic Mitochondrial Antibody Assay for the Diagnosis of Primary Biliary Cirrhosis
  10. Study of IgM Aggregation in Serum of Patients with Macroglobulinemia
  11. Trace Element Reference Values in Serum Determined by Inductively Coupled Plasma Atomic Emission Spectrometry
  12. Comparison of Two Different Methods for Measurement of Phenylalanine in Dried Blood Spots
  13. Anti-β2-Glycoprotein I ELISA: Methodology, Determination of Cut-off Values in 434 Healthy Caucasians and Evaluation of Monoclonal Antibodies as Possible International Standards
  14. Comparative Multicentre Study of a Panel of Thyroid Tests Using Different Automated Immunoassay Platforms and Specimens at High Risk of Antibody Interference
  15. A G5569A HFE Gene Polymorphism that Interferes in DNA Tests for Genetic Haemochromatosis: Who Needs to Be Re-tested?
  16. Evaluation of the Conformity of Human Growth Hormone. Concentrations Measured with the DPC Immulite® and the Nichols® Advantage™ Assays
  17. Atlas of Atherosclerosis – Progression and Regression. By Herbert C. Stary
  18. Liver Disease and Laboratory Medicine. By Ian McFarlane, Adrian Bomford and Roy Sherwood
Downloaded on 6.11.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2000.111/html
Scroll to top button